One in five people diagnosed with metastatic cancer in the Netherlands is still alive three years later, according to new ...

Find out how ADT + ARPI outperforms ADT alone in mHSPC, boosting survival and treatment persistence. Read more on real-world ...

Many things are evaluated when doctors are putting a treatment plan together for prostate cancer patients. A new study says ...

Many things are evaluated when doctors are putting a treatment plan together for prostate cancer patients. A new study says ...

The combination of enzalutamide and leuprolide significantly improves overall survival among patients with prostate cancer and a high risk for biochemical recurrence, according to a study published ...

The percentage of patients with primary metastatic cancer who are still alive three years after their initial diagnosis is ...

Stage 2 prostate cancer is considered localized, meaning the cancer is still confined entirely within the prostate gland and has not spread to nearby lymph nodes (node 0 or N0) or distant parts of the ...

University Hospitals Seidman Cancer Center researchers in Cleveland, Ohio find age should be a consideration in metastatic prostate cancer treatment plans. Results published in New England Journal of ...

New prostate cancer research from an international team led by the Center for Genetic Epidemiology at the Keck School of ...

New prostate cancer research from an international team led by the Center for Genetic Epidemiology at the Keck School of ...

To our knowledge, this is the greatest survival benefit, based upon hazard ratio, ever seen in a prostate cancer,” said study presenter Stephen J. Freedland, MD.

We demonstrate that patients with luminal B tumors derive clinically meaningful benefits … from the addition of apalutamide to secondary radiotherapy,” Dr Daniel Spratt said, adding that these ...